PARIS, FRANCE (UroToday.com) - The objective was to investigate differences between ulcerative and non-ulcerative bladder pain syndrome/interstitial cystitis (BPS/IC) patients refractory to first-line treatment of lower urinary tract symptoms and clinical response to intra-trigonal injection of Onabotulinum toxin A (OnabotA).
To read more, a FREE Urotoday registration is required. Click here to register or login above.website design firm : Web-JIVE LLC